Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1Classical hematology 1

Conditions

Myelodysplastic Syndromes 9Anemia, Aplastic 9Leukemia 8Lymphoma 6Leukemia, Myeloid, Acute 5Myeloproliferative Disorders 4Multiple Myeloma 4Hodgkin Disease 4Primary Myelofibrosis 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Lymphoma, Non-Hodgkin 3Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3Leukemia, Lymphocytic, Chronic, B-Cell 3Hematologic Neoplasms 3Polycythemia Vera 2Neutropenia, Severe Congenital, Autosomal Recessive 3 2Immunologic Deficiency Syndromes 2Histiocytosis 2Hemoglobinuria, Paroxysmal 2Congenital Abnormalities 2Bone Marrow Failure Disorders 2Blast Crisis 2Anemia, Sickle Cell 2Anemia, Refractory, with Excess of Blasts 2Anemia, Diamond-Blackfan 2beta-Thalassemia 1Thrombocythemia, Essential 1Shwachman-Diamond Syndrome 1Recurrence 1Primary Immunodeficiency Diseases 1

Interventions

Epoetin Alfa 25Darbepoetin alfa 17apixaban 9Rivaroxaban 9Dalteparin 7Heparin, Low-Molecular-Weight 6Surveys and Questionnaires 5Meropenem 5fludarabine phosphate 4Vancomycin 4Tinzaparin 4Enoxaparin 4Cyclosporine 4Cefepime 4ferric carboxymaltose 3edoxaban 3Whole-Body Irradiation 3Peripheral Blood Stem Cell Transplantation 3Mycophenolic Acid 3Ceftazidime 3Carboplatin 3Busulfan 3Antilymphocyte Serum 3Amikacin 3romiplostim 2peginesatide 2hematide 2fludarabine 2epoetin beta 2bemiparin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms × Alemtuzumab × Classical hematology × Clear all
NCT00895739 2013-08-12

Alemtuzumab and Low-Dose Cyclosporine in Treating Patients With Severe Aplastic Anemia or Acquired Marrow Failure

National Cancer Institute (NCI)

Phase 2 Unknown
50 enrolled
Classical hematology

Anemia, Aplastic, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡